First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The FIRSTMAPPP study is a randomized, double-blind, phase II, international, multicenter
study which aims to determine the efficacy of Sunitinib on the progression-free survival at
12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated
with sunitinib at a starting dose of 37.5 mg daily (continuous dosing).
Phase:
Phase 2
Details
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Collaborators:
ENSAT-CANCER European Network for the Study of Adrenal Tumours National Cancer Institute, France